WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Cunningham throws six scoreless, Vanderbilt defeats Florida 6
Freight trains to Europe and back set record in Northeast
Village in China's Henan transformed by cultural industries
Xinhua Headlines: Xi's APEC Trip to Pilot China
Kansas takes control in the ninth and beats Kansas State in the opener of the Big 12 Tournament
When Chinese martial arts, Western contemporary dance converge
Freight trains to Europe and back set record in Northeast
Massey, Perez hit homers to lead Royals in 8
Various events introduced for students at museums in Xi'an
Election 2024: Biden and the Democrats raised far less in April than Trump and the GOP
We gifted President Xi a ticket for Mombasa